Immunome Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Immunome's lead asset varegacestat received FDA acceptance of its NDA for desmoid tumors with a PDUFA target action date of April 28, 2027. Phase 3 RINGSIDE trial met its primary endpoint, showing 84% risk reduction for disease progression or death vs. placebo (HR=0.16, p<0.0001) and 56% confirmed objective response rate vs. 9% placebo. The company also initiated Phase 1 trials for IM-1617 (June 2026) and IM-3050 (July 2026), and holds $520M in cash, funding operations into 2028; Q2 2026 net loss was $73.1M with R&D expenses of $59.9M.
Why this rating
NDA acceptance with defined PDUFA date is major milestone for clinical-stage biotech; represents ~10% of market cap in cash runway remaining; positive Phase 3 data de-risks lead program but approval is 9+ months away.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.